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Use of pefloxacin as a surrogate marker to detect ciprofloxacin susceptibility in
Salmonella enterica serotypes Typhi and Paratyphi A
Safia Moin, Mohammad Zeeshan, Sidra Laiq, Ahmed Raheem, Afia Zafar

Abstract
Objective: To determine the use of pefloxacin as a surrogate marker to detect fluoroquinolone
(ciprofloxacin) susceptibility against Salmonella enterica serotypes Typhi and Paratyphi A.
Methods: The prospective, descriptive cross-sectional study was conducted at the Aga Khan University
Hospital, Karachi, from September 2016 to March 2018, and comprised Salmonella Typhi and Paratyphi
A isolates of blood cultures. Disk susceptibility tests and broth microdilution to test minimum
inhibitory concentration were performed as per standard guidelines. Data was analysed using SPSS
21.
Results: Of the 138 isolates, 91(66%) were intermediate resistant to ciprofloxacin but were resistant
to pefloxacin, 42(30%) were resistant to both ciprofloxacin and pefloxacin, and 5(4%) were susceptible
to both ciprofloxacin and pefloxacin. Of the isolates that were intermediate resistant to ciprofloxacin,
85(93%) had minimum inhibitory concentration range0.12-0.5mg\L, while 6(7%) had MIC >1mg\L
(p<0.0001).
Conclusion: Pefloxacin disk diffusion test was found to be reliable in detecting fluoroquinolone
resistance among enteric fever causing Salmonella.
Keywords: Enteric fever causing Salmonella, Ciprofloxacin, Pefloxacin, Fluoroquinolones.
(JPMA 70: 96; 2020). https://doi.org/10.5455/JPMA.8635

Introduction
Salmonella spp. cause significant morbidity and mortality
in the developing world, especially when they cause
enteric fever.1 Salmonella Typhi and Paratyphi (A, B, C)
are notorious pathogens to humans and cause 13.5
million annual episodes of enteric fever along with its
complications, especially in the low and middle income
countries (LMICs).2 Prompt and appropriate therapeutic
interventions affect the prognosis of the patient. 3
Due to good cellular uptake in macrophages and
subsequent high concentration in bile, fluoroquinolones,
especially ciprofloxacin, remains a preferred therapeutic
option to treat enteric fever in the fluoroquinolonesusceptible strains. 4,5 However, the concern about its
resistance in Salmonella Typhi and Paratyphi still exists.
Fluoroquinolone resistance is mainly caused by
chromosomal mutations in the quinolone resistancedetermining regions (QRDRs) of the topoisomerase genes
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gyrA, gyrB, parC and parE.6,7 These mutations usually
confer stepwise resistance; a single mutation is associated
with a ciprofloxacin minimum inhibitory concentration
(MIC) of 0.12-0.5 mg\L, whereas two or more mutations
result in higher MIC values.1 For many years nalidixic acid
disc (30 µg) was used for the screening of fluoroquinolone
resistance in Salmonella Typhi and Paratyphi. 8,9
Topoisomerase mutations are associated with resistance
to the nalidixic acid (MIC >32 mg\L).4,10 In addition to
the QRDR topoisomerase mutations, a number of
plasmid-mediated quinolone resistance (PMQR)
mechanisms, including qnr variants, aac (6')-Ib-cr, qepA,
and oqx AB have been described.1 These demonstrate
low-level resistance to ciprofloxacin (MIC 0.12-1.0 mg\L)
but only a modest or no increase in nalidixic acid
susceptibility (MIC 8-32 mg\L).11 Therefore, low-level
quinolone resistance is not detected by using nalidixic
acid disc.
Although the PMQR mechanisms confer only a moderate
increase in fluoroquinolone MICs, they are clinically
relevant. Patients infected with Salmonella Typhi and
Paratyphi with ciprofloxacin MICs of 0.12-1.0 mg\L have
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more treatment failures and longer times to fever
clearance than patients with isolates fully susceptible to
ciprofloxacin (MICs 0.06 mg\L).2
Since, suboptimal response of treatment has been
noticed in infections due to isolates having low-level
fluoroquinolone resistance, it is important that
laboratories should report correct antimicrobial
susceptibility results. 1 Recently, pefloxacin has been
introduced as a surrogate marker to detect ciprofloxacin
and other fluoroquinolones susceptibility.12 Therefore,
the current study was planned to check the susceptibility
of pefloxacin along with ciprofloxacin in local isolates.

Materials and Methods
The prospective, descriptive cross-sectional study was
conducted at the Department of Pathology and
Laboratory Medicine, Microbiology section, Aga Khan
University Hospital (AKUH), Karachi, from September
2016 to March 2018.
Salmonella Typhi and Paratyphi A blood isolates
regardless of gender and age were included. Non-lactose
fermenter, gram-negative bacilli were identified by using
either conventional tests or API-20E (Bio Murex, France)
sticks. Serological confirmation was done by slide and
tube agglutination method using type-specific antisera
(Difco Laboratories).
Disk susceptibility testing was performed by Kirby-Bauer
method as per Clinical Laboratory Scientific Institute
(CLSI) guidelines.13 Briefly, a suspension of test organism
equivalent to a 0.5 McFarland standard was prepared in
saline from isolated colonies grown overnight on a sheep
blood agar plate (SBA) (Oxoid Thermo Fisher,
Switzerland). Pefloxacin (5µg) and ciprofloxacin (5µg)
disks (Oxoid Thermo Fisher, Reinach, Switzerland) were
tested on Mueller Hinton Agar (Becton Dickinson MD).
Plates were incubated at 35±20C, in ambient air, for 1824 hours. Zone sizes were interpreted according to CLSI.13
An isolate was defined as ciprofloxacin-resistant (R) with
a zone of inhibition of  20mm (MIC 1mg/L); as
susceptible (S) with a zone of inhibition of 31mm (MIC
0.06 mg\L); and as intermediate resistant (IR) with a
zone of inhibition of 21-30mm (MIC 0.12 - 0.5 mg\L). An
isolate was defined as pefloxacin-resistant with a zone
of inhibition of 23mm and susceptible with a zone of
inhibition 24mm.13
For ciprofloxacin IR isolates, MIC was checked by the

broth microdilution method as per CLSI guidelines. 13
Briefly, a suspension of the test organism equivalent to
a 0.5 McFarland turbidity standard was prepared in saline
from well-isolated colonies from an overnight growth
on SBA plate. Ninety-six well U-bottom micro-titer plates
(Costar, Corning Incorporated) were used, 50µl brain
heart infusion broth was added to all the wells except
the antibiotic control wells. Further, 100µl of 16µg/ml
ciprofloxacin (Sigma Aldrich, MERCK) working solution
was dispensed in the antibiotic control wells.
Ciprofloxacin concentrations ranged from 0.007 to
16mg\L, and 50µl of organism inoculum were added to
all the wells except the antibiotic control wells. Plates
were incubated at 35±20C in ambient air for 18-24 hours.
MIC was interpreted as per CLSI guidelines. 1 3
American Type Culture Collection (ATCC) strains used as
controls in the susceptibility testing were Escherichia
coli ATCC 25922, and Pseudomonas aeruginosa ATCC
27853. The quality control results of both, MIC and disk
diffusion tests were within acceptable quality control
ranges. 13 Ethical exemption was obtained from the
institutional ethics review committee.
Data was analyzed using SPSS 21. Descriptive statistics
were calculated. Shapiro wilk test was applied to check
the normality of the variable. Mean ± standard deviation
(SD) or median (interquartile range [IQR]) was calculated
for quantitative variables. Frequencies and percentages
of qualitative variable were calculated. For 95%
confidence interval )CI), p0.05 was taken as significant.

Results
Of the 138 isolates, 96(69.5%) were Salmonella Typhi and
42(30.4%) were Paratyphi A. Of the total, 91(66%) isolates
were IR to ciprofloxacin but R to pefloxacin; 42(30.4%)
were R to both drugs; and 5(4%) were S to both
ciprofloxacin and pefloxacin. In 85(93%) IR isolates, MIC
of ciprofloxacin ranged 0.12-0.5 mg\L(IR) while 6(7%)
had MIC 1mg\L (R to ciprofloxacin) (Figure) (p<0.0001).

Discussion
Detection of low-level fluoroquinolone resistance in
Salmonella enterica serotypes Typhi and Paratyphi has
always remained challenging.1 For the past many years
nalidixic acid was being used to detect low-level
fluoroquinolone resistance among these isolates.
Unfortunately, it does not detect plasmid-mediated
fluoroquinolone resistance, as isolates appear susceptible
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Figure: Minimum inhibitory concentration (MIC) ranges of isolates reported as intermediate to ciprofloxacin by the disk diffusion method. (R: ? 1 mg/ L, IR:
between 0.12 mg/ L - 0.5 mg/ L, S ? 0.06 mg/ L).
to nalidixic acid in disc diffusion test but in reality, they
are resistant to fluoroquinolones. In many resourcelimited settings, MIC tests cannot be performed in the
majority of clinical laboratories due to cost constrains
and dearth of skilled staff. Pefloxacin has recently been
identified as a surrogate marker to detect low-level
fluoroquinolone resistance in such Salmonella spp. For
this purpose, pefloxacin disk assay was recently approved
and recommended by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) and CLSI
in 2015. 13,14 The findings of the current study are
consistent with those of other studies.1,4,15,16 Pefloxacin
disc diffusion test was able to detect low-level
fluoroquinolone resistance in local clinical isolates.
However, pefloxacin disc testing has some limitations.
It does not detect all fluoroquinolone resistance
mechanisms, such as resistance mediated by the aac(6')Ib-cr gene.1,4,17,18 Ciprofloxacin and norfloxacin are the
only fluoroquinolones which possess the piperazinyl
amide side chain which is the target for the enzyme
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encoded by aac(6')Ib-cr which acetylates the amino
nitrogen on the R7 piperazinyl substituent. 18 For
example, isolates that acquire aac(6')-Ib-cr as the sole
fluoroquinolone resistance determinant will test
susceptible to pefloxacin.19 Fortunately, this resistance
mechanism remains rare.20
We recommend the use of pefloxacin as a surrogate
marker in resource-limited laboratories to detect
ciprofloxacin resistance among enteric Salmonella Typhi
and Paratyphi.

Conclusion
Pefloxacin disk diffusion assay was found to be a
convenient, reliable and cost-effective test to determine
fluoroquinolone susceptibility among enteric fever
causing Salmonella.
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